Vasomotor symptoms Menopausal symptoms Hof flush Quality of life Curcumin Anti inflammation Vasomotor symptoms Menopausal symptoms Hof flush Quality of life
Conditions
Interventions
oral capsule curcuminoid ,placebo with the same ingredients as curcuminoids,
excluding curcuminoid powder, ensuring its safety.
Experimental Drug,Placebo Comparator Drug
Curcumin ,Placebo
Sponsors
Faculty of medicine, Ramathibodi hospital, Mahidol university
Eligibility
Sex/Gender
Female
Age
41 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Natural or surgical menopause 2. MRS Questionnaire at least one of symptoms on the somatovegetative subscale and include vasomotor symptom 3. Being willing to participate with signed inform consent 4. Communicate fluently in Thai
Exclusion criteria
Exclusion criteria: 1. Mandatory indication for Hormonal therapy (e.g., premature hypoestrogenism, osteoporosis) 2. Use of hormonal therapy or hormonal contraception within3 months before enrollment 3. Receiving the medical treatment for menopausal symptoms during the past 3 months before enrollment e.g., SSRIs, SNRIs) 4. Known or suspected hypersensitivity to the investigational medication 5. History of severe psychological diseases, such as depression or anxiety, or use of psychiatric drugs, such as anti-depressants 6. Uncontrolled underlying medical condition: Autoimmune disease, Thyroid dysfunction, ongoing cancer treatment. 7. Smoking, alcohol intake of 10 mL of pure ethanol per day or more, coffee/chocolate intake of 500 mg of caffeine per day or more,and/or suspected drug abuse 8. Incompetence or incapability of understanding the nature, meaning, and consequences of the trial. 9. Concurrent anti-oxidant supplements such as vitamin C, vitamin E or phytoestrogen 10. Contraindications for taking curcuminoids include biliary tract obstruction, gallstones, antiplatelet medications (such as aspirin), antihypertensive drugs, and oncologic medications such as doxorubicin and cyclophosphamide.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the number of hot flushes between baseline and after 12 weeks 12 weeks number of hot flushes | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Menopause rating scale 12 week Menopause rating scale,Change in MENQOL score 12 week MENQOL score | — |
Countries
Thailand
Contacts
Public ContactKitti chattrakulchai
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Outcome results
None listed